With the rapid development of biopharmaceutical technology, monoclonal antibodies (mAb), as a highly specific and affinity biomacromolecule, have shown enormous potential in fields such as disease diagnosis, treatment, and drug development. However, the development process of monoclonal antibodies is complex and time-consuming, involving cell screening, culture, antibody affinity determination, and other processes, which require extremely high accuracy and efficiency of this technology. The Beacon Optofluidic System, as an advanced cell manipulation and detection technology, has brought revolutionary changes to the field through its application in the development of monoclonal antibodies. This article will delve into the auxiliary role of Beacon Optofluidic Systems in the development and application of monoclonal antibodies.
Tumor immunotherapy, as a significant breakthrough in the field of tumor therapy in recent years, is gradually changing our traditional understanding of tumor therapy. It utilizes the patient's own immune system to recognize and attack tumor cells, with advantages such as strong targeting, minimal side effects, and long-lasting therapeutic effects. This article aims to comprehensively explore the basic principles, cutting-edge technologies, clinical applications, challenges, and prospects of tumor immunotherapy.
In the fields of medicine and bioscience, experimental models and testing platforms are crucial for disease research, drug development, and personalized healthcare. Traditional experimental methods, such as animal models and cell culture, although provide strong support for scientific research, still have limitations in simulating the real human environment and reactions. The emergence of Organ on a Chip technology has brought revolutionary changes to medical research due to its miniaturization, high simulation, and high efficiency.
With the increasing demand for precision medicine and personalized treatment, antibody drugs, as high-precision and highly specific biological agents, are becoming increasingly prominent in disease treatment. However, traditional antibody discovery methods, such as hybridoma technology, have many limitations, such as insufficient diversity of antibody libraries and long screening cycles. Therefore, developing new antibody discovery techniques is particularly important. The Beacon Optofluidic System, as a cell manipulation technology based on optical principles, provides a new solution for the discovery of antibodies. This article will explore in detail the role of Beacon Optofluidic System in antibody discovery, providing new ideas and methods for the development of antibody drugs.
Contact Hotline：010-59220628 / 17777826188 / 13964162110
E-mail：zhangwei@redbert.com
Business address：Room 602a, 6 / F, building 2, Xin 2, East Third Ring North Road, Chaoyang District, Beijing
Scan for more information
CopyRight © 2022 Copyright Redbert (Beijing) Biotechnology Co., Ltd ALL RESERVED. Record No：京ICP备19049297号-1
Technical support：FUKU